umotif, a patient data capture platform, has raised £5 million in a Series A investment round led by existing investor AlbionVC.
Its app supports patients monitor themselves through clinical studies, and is typically sold into life sciences companies for patients to submit their data.
The app has recently been used as a data capture tool at Hampshire Hospitals NHS Foundation Trust to support a 4 – 6 month study to investigate whether using sinus rinses and mouth washes, reduces viral colonisation of the oropharynx in people who test positive with Covid-19.
It’s being used if a staff member tests positive, they will then monitor their symptoms remotely while self-isolating at home.
Dr Afroze Khan, an Ear, Nose, and Throat Surgeon at Basingstoke and North Hampshire Foundation Trust Hospital, said: “The umotif platform is beautifully designed and serves our study needs very well. We needed to implement a fully virtual approach and at rapid speed.”
“Not only does the umotif technology facilitate this but their team partners in such a collaborative way our trial was able to go live within three weeks”.
The technology is now being used in 26 countries, supporting a range of studies such as tracking pain levels to rare diseases.
The company said the funding will be used to accelerate growth and develop further patient-centric and decentralised solutions.
Bruce Hellman, CEO and Co-Founder of umotif, said: “We’re excited to help our customers implement patient-centred research designs by using the umotif platform to capture high-quality data.”
“This new funding will rapidly accelerate our development and will ultimately help our customers to get new therapies to patients faster.”
Dr. Andrew Elder, Deputy Managing Partner at AlbionVC, said: “Now more than ever, having access to reliable patient data during clinical trials is crucial. umotif’s platform is built with patients in mind; designed to help academics, researchers and healthcare professionals to capture the best quality data in a way that suits the participants. It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the speed and efficiency with which therapies can reach and help millions of patients.”
